Phase 1 and 3 trials demonstrated improved survival rates, with new treatment strategies for EGFR-mutated NSCLC, HER2+ breast cancer, and small-cell lung cancer. AI innovations, such as the ASCO ...
Standardized PSADT calculations are crucial for timely prostate cancer treatment, potentially preventing metastasis and reducing treatment costs. Casdatifan shows promise in clear cell RCC, with a 100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results